The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
G. Lopes
Research Funding - AstraZeneca
J. Segel
No relevant relationships to disclose
D. S. W. Tan
Research Funding - AstraZeneca
Y. Do
Research Funding - AstraZeneca
T. Mok
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
E. Finkelstein
Research Funding - AstraZeneca